Prostate Cancer News on BioPortfolio

MetaStat Inc. Announces Allowance of Patent Claims

THE WOODLANDS Texas July 10 2012 PRNewswire &160;MetaStat Inc. OTCBB MTST announced today that it has received notice of allowance from the U.S. Patent Office for U.S. Patent Application No. 11659514 and notice of allowance of European Patent Applicati...

Epistem Holdings Plc PreClose Trading Update

Epistem AIM EHP the rapidly growing biotechnology company announced on 29 July a preclose trading statement for the year ended 30th June 2010. Following a very positive year during which sales in all of the Company's business divisions have made strong pro...

Best of the Northwest Biomedical sector

Bionow the Northwest Regional Development Agency's NWDA biomedical cluster support group held their annual Northwest Biomedical Awards at Mere Golf & Country Club on Thursday 11 November. The event attended by 270 guests is a showcase of the very ...

Evgen secures VC Funding

The undisclosed investment from the North West Fund for Biomedical which is managed by earlystage venture capital firm Spark Impact will see the business move from Sheffield to Liverpool Science Park.EV Group an investor in Evgen since its inception also p...

AstraZeneca commits £120m to Macclesfield factory

Pharmaceutical group AstraZeneca will invest £120m extending its factory in Macclesfield which makes the prostate cancer drug Zoladex.The company said the investment will secure 300 jobs and create 200 temporary role during construction work a...

Epistem announces further partnership with The University of Manchester

Epistem Holdings Plc LSE EHP Manchester UK the UK biotechnology and personalised medicine company announce a further partnership with The University of Manchester to further the understanding of the biology of chronic delayed wound healing associated with ...

Successful £2.0 million Fundraising

Evgen Pharma a clinical stage drug development company focused on the treatment of cancer and neurological conditions today announces that it has successfully raised £2.0m in an oversubscribed fundraising supported by existing shareholders and ne...

Articles Custirsen OGX011 combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castrationresistant prostate cancer previously treated with docetaxel AFFINITY a randomised openlabel intern

We noted no survival benefit in men with metastatic castrationresistant prostate cancer with the addition of custirsen to cabazitaxel and prednisone treatment. Cabazitaxel and prednisone remains the standard of care for patients with metastatic castrationr...

Pages